Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Anti-ageing therapies

- PMLiVE

Ex-Pharmacyclics CEO invests $25m in Summit

After Duchenne drug failure, UK biotech looks to new anti-infective

Navigating the antibiotic resistance crisis

Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Blue Latitude Health

Report: Achieving launch excellence in the challenging healthcare markets of today

Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...

Blue Latitude Health

- PMLiVE

Moderna files record $500m IPO for RNA pipeline

Could be the largest IPO for a biotech start-up

- PMLiVE

MedCity sets up advanced therapy research network

Aims to capitalise on UK's expertise in cutting-edge field

- PMLiVE

New leader at Medivir after setbacks

Christine Lind departs Swedish biotech

- PMLiVE

Orchard plans IPO as gene therapy pipeline advances

UK biotech seeks funds for expanded rare disease portfolio

- PMLiVE

Genetic counsellors: the new healthcare influencers?

Blue Latitude Health explores the relationship between physicians and genetic counsellors, and the impact this has on turning precision medicine into a reality for oncology patients.

Blue Latitude Health

Mastering the precision medicine opportunity

The rise of precision medicine will transform the pharma business model, challenging the way we commercialise therapies. BLH Senior Consultant and precision medicine expert David Cooney, reveals how you can...

Blue Latitude Health

- PMLiVE

DNA damage specialists Artios Pharma raises $84m

Team behind development of Lynparza focus on next-gen DDR inhibitors

- PMLiVE

Vernalis accepts £33m takeover offer from Ligand Pharma

Biotech buyout brings team of 70 scientists in Cambridge, UK

- PMLiVE

China’s BeiGene raises $903m from Hong Kong IPO

Mammoth debut might have exceeded $1bn but for market jitters

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links